Atea Pharmaceuticals reported total assets of $232.28M and total liabilities of $28.12M for the quarter ended Jun 2026, down 40.7% year over year. This balance sheet covers 28 quarters of results from Sep 2019 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Balance Sheet | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accumulated Depreciation | 0.16M | 0.27M | 0.69M | 1.10M | 1.52M | |||||||||||||||||||||||
| Assets | ||||||||||||||||||||||||||||
| Current Assets | ||||||||||||||||||||||||||||
| Cash & EquivalentsCash & Equiv. | 839.66M | 764.38M | 705.54M | 684.48M | 176.41M | 188.46M | 183.25M | 213.70M | 137.89M | 143.82M | 160.91M | 243.39M | 98.46M | 64.70M | 119.39M | 87.72M | 77.34M | 95.71M | 79.32M | 76.55M | ||||||||
| Receivables - NetNet Receivables | 4.51M | |||||||||||||||||||||||||||
| Receivables - OtherOther Receivables | ||||||||||||||||||||||||||||
| Receivables | 4.51M | |||||||||||||||||||||||||||
| Prepaid Assets | 3.29M | 8.03M | 7.69M | 4.97M | 12.45M | 14.21M | 11.90M | 12.76M | 8.19M | 12.35M | 7.27M | 4.16M | 4.09M | 7.63M | 8.27M | 5.89M | 6.83M | 9.16M | 7.19M | 9.20M | ||||||||
| Current Assets | 842.95M | 772.40M | 713.23M | 689.45M | 681.93M | 660.92M | 632.39M | 620.83M | 603.32M | 590.46M | 548.76M | 506.37M | 486.91M | 462.36M | 433.71M | 385.60M | 336.14M | 310.99M | 263.20M | 228.66M | ||||||||
| Non-Current Assets | ||||||||||||||||||||||||||||
| Property, Plant & Equipment (Net) | 0.03M | 0.02M | 0.76M | 1.90M | 1.81M | 1.71M | 1.60M | 1.50M | 1.39M | 1.29M | 1.19M | 1.08M | 0.98M | 0.87M | 0.77M | 0.67M | 0.56M | 0.46M | 0.35M | 0.25M | ||||||||
| Other Non-Current Assets | 0.30M | 0.30M | 0.30M | 0.30M | 0.30M | 1.49M | 0.20M | 0.20M | 1.40M | 1.40M | 1.40M | 1.40M | 1.68M | 0.20M | 4.39M | 4.39M | 5.47M | 3.14M | 3.05M | 3.05M | ||||||||
| Non-Current Assets | 0.56M | 0.49M | 3.96M | 4.89M | 4.64M | 5.79M | 5.74M | 5.20M | 4.76M | 4.51M | 4.26M | 4.01M | 4.05M | 2.31M | 6.26M | 6.00M | 6.83M | 4.23M | 3.88M | 3.62M | ||||||||
| Assets | 843.50M | 772.89M | 717.19M | 694.34M | 686.58M | 666.71M | 638.13M | 626.03M | 608.08M | 594.97M | 553.03M | 510.38M | 490.96M | 464.67M | 439.96M | 391.61M | 342.96M | 315.22M | 267.08M | 232.28M | ||||||||
| Liabilities | ||||||||||||||||||||||||||||
| Current Liabilities | ||||||||||||||||||||||||||||
| Accounts Payables | 22.19M | 4.53M | 3.66M | 13.88M | 1.12M | 2.55M | 0.70M | 3.96M | 0.40M | 4.25M | 21.14M | 5.47M | 5.79M | 4.46M | 7.39M | 8.84M | 3.52M | 12.95M | 9.45M | 10.06M | ||||||||
| Payables | 22.19M | 4.53M | 3.66M | 13.88M | 1.12M | 2.55M | 0.70M | 3.96M | 0.40M | 4.25M | 21.14M | 5.47M | 5.79M | 4.46M | 7.39M | 8.84M | 3.52M | 12.95M | 9.45M | 10.06M | ||||||||
| Accumulated Expenses | 47.68M | 52.15M | 24.84M | 10.49M | 13.80M | 15.21M | 10.93M | 11.46M | 17.75M | 27.36M | 19.41M | 20.37M | 18.61M | 13.35M | 13.55M | 10.45M | 15.83M | 26.00M | 23.29M | 17.64M | ||||||||
| Current Taxes | 12.00M | 2.57M | 2.57M | 0.01M | 0.71M | 0.10M | 0.18M | 0.02M | ||||||||||||||||||||
| Current Deferred Revenue | 192.18M | |||||||||||||||||||||||||||
| Total Current Liabilities | 262.05M | 56.88M | 28.61M | 25.11M | 15.63M | 18.48M | 12.36M | 16.16M | 18.89M | 32.38M | 41.31M | 26.62M | 25.19M | 18.60M | 21.75M | 20.12M | 20.18M | 39.78M | 33.37M | 28.12M | ||||||||
| Non-Current Liabilities | ||||||||||||||||||||||||||||
| Preferred Stock Liabilities | ||||||||||||||||||||||||||||
| Operating Leases | 2.76M | 2.77M | 2.58M | 2.40M | 2.21M | 2.03M | 1.83M | 1.64M | 1.45M | 1.25M | 1.04M | 0.84M | 0.63M | 0.42M | 0.21M | |||||||||||||
| Other Non-Current Liabilities | 5.93M | 5.93M | 6.01M | 5.17M | 5.25M | 5.37M | 5.49M | 5.62M | 5.76M | 5.90M | 6.05M | 6.20M | 6.36M | 6.50M | 6.64M | 6.79M | ||||||||||||
| Total Non-Current Liabilities | 56.88M | 31.37M | 27.87M | 18.22M | 20.88M | 14.58M | 18.18M | 20.73M | 34.02M | 42.76M | 27.86M | 26.23M | 19.45M | 22.38M | 20.54M | 20.39M | 39.78M | |||||||||||
| Total Liabilities | 262.05M | 62.81M | 37.30M | 33.88M | 23.39M | 26.14M | 19.95M | 23.68M | 26.34M | 39.78M | 48.66M | 33.91M | 32.44M | 25.80M | 28.88M | 27.19M | 27.18M | 39.78M | 33.37M | 28.12M | ||||||||
| Shareholder's Equity | ||||||||||||||||||||||||||||
| Common Equity | 581.45M | 710.08M | 679.88M | 660.46M | 663.19M | 640.57M | 618.18M | 602.35M | 581.73M | 555.19M | 504.37M | 476.47M | 458.52M | 438.87M | 411.08M | 364.42M | 315.78M | 275.43M | 233.71M | 204.16M | ||||||||
| Liabilities and Shareholders Equity | 843.50M | 772.89M | 717.19M | 694.34M | 686.58M | 666.71M | 638.13M | 626.03M | 608.08M | 594.97M | 553.03M | 510.38M | 490.96M | 464.67M | 439.96M | 391.61M | 342.96M | 315.22M | 267.08M | 232.28M | ||||||||
| Retained Earnings | -61.10M | 56.03M | 13.95M | -17.38M | -25.45M | -59.88M | -95.35M | -123.53M | -156.67M | -195.84M | -259.00M | -299.53M | -330.68M | -364.22M | -398.49M | -435.65M | -477.70M | -522.57M | -568.01M | -600.94M |
Pull Atea Pharmaceuticals's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=AVIR&statement=BS&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "AVIR", "statement": "BS", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=AVIR&statement=BS&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();